Treating Patients With NSCLC and High PD-L1 Expression in the First Line

Cemiplimab 5-Year Data Show Improved Survival in High PD-L1 NSCLC

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Reviewing Key Trials Shaping IO Monotherapy in Advanced Lung Cancer

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with high PD-L1.

Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC

During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer.

Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer

During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.

Part 2: Discussing Brain Metastases and Immunotherapy Duration in NSCLC

During a live virtual event, Ravi Salgia, MD, PhD, discussed treatment considerations for a patient with non–small cell lung cancer with a brain metastasis.

Part 1: Challenges of Choosing Single-Agent Immunotherapy for NSCLC

During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.